00:24:30 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Vicore Pharma Holding är ett läkemedelsbolag. Bolaget är idag verksamma inom forskning och utveckling av molekyler med agnostisk verkan på AT2 receptorn inom Renin Angiotensin System (RAS), som påverkar vätske- och saltbalansen i kroppen. Vicore Pharma ingår vanligtvis licensavtal med andra läkemedelsbolag i branschen och har idag verksamhet på global nivå. Bolaget grundades 2000 och har sitt huvudkontor i Mölndal.

Kalender

2019-10-18 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-16 Ordinarie utdelning VICO 0.00 SEK
2019-05-15 Kvartalsrapport 2019-Q1
2019-05-15 Årsstämma 2018
2019-02-22 Bokslutskommuniké 2018
2019-01-07 Extra Bolagsstämma 2018
2018-10-19 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-06-13 Årsstämma 2017
2018-05-09 Ordinarie utdelning VICO 0.00 SEK
2018-05-08 Kvartalsrapport 2018-Q1
2018-02-21 Bokslutskommuniké 2017
2017-10-19 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-05-11 Ordinarie utdelning VICO 0.00 SEK
2017-05-10 Kvartalsrapport 2017-Q1
2017-05-10 Årsstämma 2016
2017-03-27 Extra Bolagsstämma 2017
2017-02-24 Bokslutskommuniké 2016
2016-10-13 Kvartalsrapport 2016-Q3
2016-07-08 Kvartalsrapport 2016-Q2
2016-04-27 Årsstämma 2015
2016-04-15 Kvartalsrapport 2016-Q1
2016-02-26 Ordinarie utdelning VICO 0.00 SEK
2016-02-25 Bokslutskommuniké 2015
2019-05-15 17:30:00

The following resolutions were passed at the annual general meeting (the "AGM") of Vicore Pharma Holding AB (publ) ("Vicore Pharma") on 15 May 2019.

Adoption of income statement and balance sheet for the financial year 2018 and discharge from liability

The AGM resolved to adopt the income statement and the consolidated income statement for the financial year 2018 as well as the balance sheet and consolidated balance sheet as of 31 December 2018. The members of the board of directors and the managing director were discharged from liability for the financial year 2018.

Allocation of profit or loss

The AGM resolved, in accordance with the board of directors' proposal, that no dividend shall be paid for 2018 and that the results of the company shall be carried forward.

Election of board members and auditors, and fees to the board of directors and auditors

The AGM resolved, in accordance with the nomination committee's proposal, to re-elect Leif Darner, Jacob Gunterberg, Maarten Kraan, Sara Malcus, Hans Schikan and Peter Strömas members of the board of directors for the period until the end of the next annual general meeting. Leif Darner was re-elected as the chairman of the board of directors. The audit firm EY AB was re-elected auditor of the company for the period until the end of the next annual general meeting. 

The AGM further resolved on directors' fees in accordance with the nomination committee's proposal. The AGM further resolved, in accordance with the nomination committee's proposal, that the fee to the auditor shall be paid as per approved statement of costs.

Nomination committee for the next annual general meeting

The AGM resolved, in accordance with the nomination committee's proposal, on principles for appointing the nomination committee. In short, the principles imply that the nomination committee should be composed of the chairman of the board of directors together with one representative of each of the three largest shareholders in terms of votes, based on ownership in the company as of 31 August 2019.

Guidelines on remuneration to group management

The AGM resolved, in accordance with the proposal from the board of directors, on guidelines for remuneration to group management. In short, the guidelines state that remuneration within Vicore Pharma shall be based on principles of performance, competitiveness and fairness and consist of fixed remuneration, variable remuneration, share and share price-related incentive programs, pension and other benefits.

Authorization to issue new shares

The AGM resolved to, in accordance with the board of directors' proposal, authorize the board of directors, at one or several occasions, with or without deviation from the shareholders' preferential rights and for the period up until the next annual general meeting, to increase the company's share capital by issuing new shares. The number of shares that may be issued under the authorization may not entail a dilution effect of more than 20 per cent.

Mölndal, 15 May 2019
Vicore Pharma Holding AB (publ)

For further information, please contact:

Carl-Johan Dalsgaard, CEO, Tel: +46 70 975 98 63, carl-johan.dalsgaard@vicorepharma.com

Hans Jeppsson, CFO, Tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com

The information was submitted for publication, through the agency of the contact persons set out above, on 15 May 2019 at  17:30 CEST.